Bristol-Myers Squibb (NYSE:BMY) SVP Sells $38,934.00 in Stock

Bristol-Myers Squibb (NYSE:BMY) SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $55.28 on Thursday. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The company has a market capitalization of $112.12 billion, a price-to-earnings ratio of -15.40, a PEG ratio of 13.14 and a beta of 0.44. The firm’s 50-day moving average is $51.69 and its 200 day moving average is $46.72. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $56.80.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.00 EPS. Research analysts predict that Bristol-Myers Squibb will post 0.83 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.34%. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

Hedge Funds Weigh In On Bristol-Myers Squibb

A number of hedge funds have recently added to or reduced their stakes in the stock. Norden Group LLC lifted its position in shares of Bristol-Myers Squibb by 30.2% in the 1st quarter. Norden Group LLC now owns 13,846 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 3,213 shares during the period. Rehmann Capital Advisory Group lifted its position in shares of Bristol-Myers Squibb by 13.1% in the 1st quarter. Rehmann Capital Advisory Group now owns 26,607 shares of the biopharmaceutical company’s stock worth $1,443,000 after purchasing an additional 3,080 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $240,000. Callan Capital LLC purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $310,000. Finally, Avidian Wealth Solutions LLC lifted its position in shares of Bristol-Myers Squibb by 5.9% in the 1st quarter. Avidian Wealth Solutions LLC now owns 6,369 shares of the biopharmaceutical company’s stock worth $345,000 after purchasing an additional 355 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BMY. UBS Group upped their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. Jefferies Financial Group upped their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. Finally, BMO Capital Markets upped their target price on shares of Bristol-Myers Squibb from $53.00 to $57.00 and gave the company a “market perform” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $53.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.